Caixin
Jul 06, 2022 04:32 AM
BUSINESS

Japan’s Shionogi Seeks China Approval for Covid Treatment

China in February granted conditional approval for emergency use of Paxlovid.
China in February granted conditional approval for emergency use of Paxlovid.

Japanese drugmaker Shionogi & Co. Ltd. applied for Chinese approval to sell its antiviral treatment for Covid-19, racing to become the second oral therapy to land in the country after Pfizer Inc.’s Paxlovid.

Osaka-based Shionogi said an application for marketing the drug, known as S-217622, was submitted to China’s National Medical Product Administration (NMPA) by its joint venture with Chinese insurer Ping An Insurance Group Co. — Ping An-Shionogi.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: Hong Kong ‘Homecoming’ Listings
00:00
00:00/00:00